Contemporary murine models in preclinical astrocytoma drug development

Neuro Oncol. 2015 Jan;17(1):12-28. doi: 10.1093/neuonc/nou288. Epub 2014 Sep 21.


Despite 6 decades of research, only 3 drugs have been approved for astrocytomas, the most common malignant primary brain tumors. However, clinical drug development is accelerating with the transition from empirical, cytotoxic therapy to precision, targeted medicine. Preclinical animal model studies are critical for prioritizing drug candidates for clinical development and, ultimately, for their regulatory approval. For decades, only murine models with established tumor cell lines were available for such studies. However, these poorly represent the genomic and biological properties of human astrocytomas, and their preclinical use fails to accurately predict efficacy in clinical trials. Newer models developed over the last 2 decades, including patient-derived xenografts, genetically engineered mice, and genetically engineered cells purified from human brains, more faithfully phenocopy the genomics and biology of human astrocytomas. Harnessing the unique benefits of these models will be required to identify drug targets, define combination therapies that circumvent inherent and acquired resistance mechanisms, and develop molecular biomarkers predictive of drug response and resistance. With increasing recognition of the molecular heterogeneity of astrocytomas, employing multiple, contemporary models in preclinical drug studies promises to increase the efficiency of drug development for specific, molecularly defined subsets of tumors.

Keywords: astrocytoma; drug development; genomics; glioblastoma; mouse models.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Astrocytoma / drug therapy*
  • Astrocytoma / genetics*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / genetics*
  • Cell Line, Tumor
  • Disease Models, Animal*
  • Drug Discovery*
  • Glioblastoma / drug therapy
  • Glioblastoma / genetics
  • Humans
  • Mice


  • Antineoplastic Agents